Nura Bio

About:

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases.

Website: https://nurabio.com

Twitter/X: nurabio_

Top Investors: Samsara BioCapital, Euclidean Capital, The Column Group, Sanofi Ventures

Description:

Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases. Nura Bio’s drug candidate, NB-4746, is designed to inhibit the SARM1 protein, which plays a significant role in axon degeneration. This drug has shown promise in preclinical studies for preventing nerve damage and is currently advancing toward phase 1b/2 clinical trials in 2025. The company has raised $140 million in financing to support this and other neuroprotective drug programs.